2-(6-fluorochroman-8-yloxy)ethylamine | 211692-35-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 2-(6-fluorochroman-8-yloxy)ethylamine
• 英文别名: 2-[(6-fluoro-3,4-dihydro-2H-chromen-8-yl)oxy]ethanamine
• CAS: 211692-35-2
• 化学式: C₁₁H₁₄FNO₂
• 分子量: 211.236
• InChiKey: QHPCUVXBWOQMGO-UHFFFAOYSA-N

物化性质

• 熔点：
  68-70 °C
• 沸点：
  325.5±42.0 °C(Predicted)
• 密度：
  1.202±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(2-溴乙基)吲哚 、 2-(6-fluorochroman-8-yloxy)ethylamine 在 三乙胺 作用下， 以 二甲基亚砜 为溶剂， 反应 12.0h， 以34%的产率得到[2-(6-Fluorochroman-8-yloxy)-ethyl]-[2-(1H-indol-3-yl)-ethyl]-amine
  参考文献：
  名称：

  Studies toward the Discovery of the Next Generation of Antidepressants. 3. Dual 5-HT_1A and Serotonin Transporter Affinity within a Class of N-Aryloxyethylindolylalkylamines

  摘要：

  N-Aryloxylethylindolealkylamines (5) having dual 5-HT transporter and 5-HT1A affinity are described. These compounds represent truncated analogues of our previously reported piperidinyl derivatives (3). Compounds in this investigation were found to have more similar affinities and functional activities for the 5-HT1A receptor and 5-HT transporter. Though 5-HT1A antagonism is not consistently observed throughout series 5, several molecular features were found to be essential to obtain high and balanced activities. The proper placement of a heteroatom in the aryl ring and the length of the linkage used to tether the indole moiety had significant influence on 5-HT1A and 5-HT transporter affinities. Introduction of a halogen into the aryl ring usually lowered intrinsic activity and in some cases led to full 5-HT1A antagonists. Compounds 33 and 34 were observed to be full 5-HT1A antagonists with K-i values of approximately 30 nM for the 5-HT1A receptor and K-i values of 5 and 0.5 nM for the 5-HT transporter, respectively. Unfortunately, similar to our previous series (3), compounds in this report also had high affinity for the alpha(1) receptor.

  DOI：

  10.1021/jm0304010
• 作为产物：
  描述：

  6-氟苯并二氢吡喃-8-醇 在 sodium azide 、 水 、 potassium carbonate 、 三苯基膦 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 、 丁酮 为溶剂， 反应 60.0h， 生成 2-(6-fluorochroman-8-yloxy)ethylamine
  参考文献：
  名称：

  Studies toward the Discovery of the Next Generation of Antidepressants. 3. Dual 5-HT_1A and Serotonin Transporter Affinity within a Class of N-Aryloxyethylindolylalkylamines

  摘要：

  N-Aryloxylethylindolealkylamines (5) having dual 5-HT transporter and 5-HT1A affinity are described. These compounds represent truncated analogues of our previously reported piperidinyl derivatives (3). Compounds in this investigation were found to have more similar affinities and functional activities for the 5-HT1A receptor and 5-HT transporter. Though 5-HT1A antagonism is not consistently observed throughout series 5, several molecular features were found to be essential to obtain high and balanced activities. The proper placement of a heteroatom in the aryl ring and the length of the linkage used to tether the indole moiety had significant influence on 5-HT1A and 5-HT transporter affinities. Introduction of a halogen into the aryl ring usually lowered intrinsic activity and in some cases led to full 5-HT1A antagonists. Compounds 33 and 34 were observed to be full 5-HT1A antagonists with K-i values of approximately 30 nM for the 5-HT1A receptor and K-i values of 5 and 0.5 nM for the 5-HT transporter, respectively. Unfortunately, similar to our previous series (3), compounds in this report also had high affinity for the alpha(1) receptor.

  DOI：

  10.1021/jm0304010

文献信息

• N-aryloxyethyl-indoly-alkylamines for the treatment of depression
  申请人：American Home Products Corp.

  公开号：US06121307A1

  公开（公告）日：2000-09-19

  Compounds useful for alleviating symptoms of depression are provided which have the following formula: wherein: R.sub.1 is hydrogen, lower alkyl or aryl; R.sub.2 is hydrogen, lower alkyl, phenyl or substituted phenyl; X and Y are each, independently, hydrogen, lower alkyl, lower alkoxy, or halogen, or together combine with the carbon atoms to which they are attached to complete a pyranyl, dihydrofuranyl, furanyl, or dioxanyl, group; Z is hydrogen, halogen or lower alkoxy; with the proviso that when X, Y or Z represent lower alkoxy, they are not present at the ortho position; W is hydrogen, halogen, lower alkyl, cyano or a trifluoromethyl group; and n is 2-5; or pharmaceutically acceptable salts thereof.

  提供了有用于缓解抑郁症状的化合物，其具有以下公式：其中：R.sub.1是氢、低级烷基或芳基；R.sub.2是氢、低级烷基、苯基或取代苯基；X和Y各自独立地是氢、低级烷基、低级烷氧基或卤素，或与它们连接的碳原子结合以形成吡喃基、二氢呋喃基、呋喃基或二氧杂环基；Z是氢、卤素或低级烷氧基；条件是当X、Y或Z代表低级烷氧基时，它们不位于邻位；W是氢、卤素、低级烷基、氰基或三氟甲基基团；n为2-5；或其药学上可接受的盐。
• N-arloxyethyl-alkylamines for the treatment of depression
  申请人：American Home Products Corp

  公开号：US06291683B1

  公开（公告）日：2001-09-18

  Compounds useful for alleviating symptoms of depression are provided which have the following formula: wherein: R1 is hydrogen, lower alkyl or aryl; R2 is hydrogen, lower alkyl, phenyl or substituted phenyl; X and Y are each, independently, hydrogen, lower alkyl, lower alkoxy, or halogen, or together combine with the carbon atoms to which they are attached to complete a cyclopentyl, cyclohexyl, phenyl, pyrrolyl, pyranyl, pyridinyl, dihydrofuranyl, furanyl, dioxanyl, oxazolyl or isoxazolyl group; Z is hydrogen, halogen or lower alkoxy; with the proviso that when X, Y or Z represent lower alkoxy, they are not present at the ortho position; W is hydrogen, halogen, lower alkyl, cyano or a trifluoromethyl group; and n is 2-5; or pharmaceutically acceptable salts thereof.

  提供了用于缓解抑郁症状的化合物，其具有以下结构式：其中：R1为氢、低级烷基或芳基；R2为氢、低级烷基、苯基或取代苯基；X和Y各自独立地为氢、低级烷基、低级烷氧基或卤素，或者结合它们所连接的碳原子以完成环戊基、环己基、苯基、吡咯基、吡喃基、吡啶基、二氢呋喃基、呋喃基、二氧杂环己基、噁唑基或异噁唑基；Z为氢、卤素或低级烷氧基；但当X、Y或Z表示低级烷氧基时，它们不出现在邻位；W为氢、卤素、低级烷基、氰基或三氟甲基基团；n为2-5；或其药学上可接受的盐。
• N-aryloxyethylamine derivatives for the treatment of depression
  申请人：American Home Products Corp.

  公开号：US06110956A1

  公开（公告）日：2000-08-29

  Compounds effective in treating disorders of the serotonin-affected neurological systems are provided, such compounds having the following formula: ##STR1## wherein: R.sub.1 and R.sub.2 are each, independently, hydrogen, halogen, CF.sub.3, lower alkyl, lower alkoxy, MeSO.sub.2, or together can form a 5-7 membered carbocyclic or heterocyclic ring; R.sub.3 is alkoxy, halogen, hydrogen or carbamoyl; R.sub.4 is hydrogen, hydroxy, lower alkyl, or lower alkoxy; R.sub.5 is hydrogen, lower alkyl, or halogen; R.sub.6 is hydrogen, lower alkyl, or phenyl; R.sub.7 is hydrogen, lower alkyl, lower alkoxy, halogen, CN, CF.sub.3, or hydroxy; and X is (CH.sub.2).sub.n, wherein n is 0 to 3; or pharmaceutically acceptable salts thereof.

  提供了用于治疗受血清素影响的神经系统疾病的化合物，该化合物具有以下结构式：##STR1## 其中：R.sub.1和R.sub.2各自独立地是氢、卤素、CF.sub.3、较低的烷基、较低的烷氧基、MeSO.sub.2，或者一起形成5-7个成员的碳环或杂环；R.sub.3是烷氧基、卤素、氢或者氨基甲酰基；R.sub.4是氢、羟基、较低的烷基或较低的烷氧基；R.sub.5是氢、较低的烷基或卤素；R.sub.6是氢、较低的烷基或苯基；R.sub.7是氢、较低的烷基、较低的烷氧基、卤素、CN、CF.sub.3或羟基；X是(CH.sub.2).sub.n，其中n为0至3；或其药学上可接受的盐。
• Synthesis and Pharmacological Characterization of Novel 6-Fluorochroman Derivatives as Potential 5-HT_1A Receptor Antagonists
  作者：Tomoyuki Yasunaga、Takenori Kimura、Ryo Naito、Toru Kontani、Fumikazu Wanibuchi、Hiroshi Yamashita、Tamako Nomura、Shin-ichi Tsukamoto、Tokio Yamaguchi、Toshiyasu Mase

  DOI：10.1021/jm9707840

  日期：1998.7.1

  A series of novel 6-fluorochroman derivatives was prepared and evaluated as antagonists for the 5-HT1A receptor. N-2- [[(6-Fluorochroman-8-yl)oxy]ethyl]-4-(4-methoxyphenyl)butylamine (3; J. Med. Chem. 1997, 40, 1252-1257) was chosen as a lead, and structural modifications were done on the aliphatic portion of the chroman ring, the tether linking the middle amine and the terminal aromatic ring, the aromatic ring, and lastly the amine. Radioligand binding assays proved that the majority of the novel compounds behaved as good to excellent ligands at the 5-HT1A receptor, some of which were selective with respect to alpha(1)-adrenergic and D-2-dopaminergic receptors. The antagonist activity of the compounds was assessed in the forskolin-stimulated adenylate cyclase assays in CHO cells expressing the human 5-HT1A receptors. Among the modifications attempted, introduction of an oxo or an optically active hydroxy moiety at the chroman C-4 position was effective in ameliorating the receptor selectivity. Six analogues were selected through the in vitro screeds and further evaluated for their in vivo activities. A 4-oxochroman derivative (31n), having a terminal 1,3-benzodioxole ring, demonstrated antagonist activities toward 8-OH-DPAT-induced behavioral and electrophysiological responses in rats.
• N-ARYLOXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF DEPRESSION
  申请人：Wyeth

  公开号：EP1068184B1

  公开（公告）日：2002-09-04